Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share
Portfolio Pulse from Benzinga Newsdesk
Fulgent Genetics expects its 2024 core revenue to be approximately $280 million, with a non-GAAP loss improvement from approximately ($1.05) per share to approximately ($0.30) per share. This is in line with the consensus revenue estimate of $280.18 million but better than the consensus loss estimate of $(0.92) per share.
August 02, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fulgent Genetics expects 2024 core revenue of $280M and a non-GAAP loss improvement to ($0.30) per share, better than the consensus loss estimate of $(0.92) per share.
The company's revenue projection is in line with expectations, but the significant improvement in the non-GAAP loss per share compared to the consensus estimate is likely to be viewed positively by investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100